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Abstract
Background: Many stroke survivors have significant long-term gait impairment, often involving foot drop. Current
physiotherapies provide limited recovery. Orthoses substitute for ankle strength, but they provide no lasting
therapeutic effect. Brain-computer interface (BCI)-controlled functional electrical stimulation (FES) is a novel
rehabilitative approach that may generate permanent neurological improvements. This study explores the safety
and feasibility of a foot-drop-targeted BCI-FES physiotherapy in chronic stroke survivors.
Methods: Subjects (n = 9) operated an electroencephalogram-based BCI-FES system for foot dorsiflexion in 12
one-hour sessions over four weeks. Gait speed, dorsiflexion active range of motion (AROM), six-minute walk distance
(6MWD), and Fugl-Meyer leg motor (FM-LM) scores were assessed before, during, and after therapy. The primary safety
outcome measure was the proportion of subjects that deteriorated in gait speed by ≥0.16 m/s at one week or
four weeks post-therapy. The secondary outcome measures were the proportion of subjects that experienced a
clinically relevant decrease in dorsiflexion AROM (≥2.5°), 6MWD (≥20 %), and FM-LM score (≥10 %) at either
post-therapy assessment.
Results: No subjects (0/9) experienced a clinically significant deterioration in gait speed, dorsiflexion AROM, 6MWT
distance, or FM-LM score at either post-therapy assessment. Five subjects demonstrated a detectable increase (≥0.06 m/s)
in gait speed, three subjects demonstrated a detectable increase (≥2.5°) in dorsiflexion AROM, five subjects demonstrated
a detectable increase (≥10 %) in 6MWD, and three subjects demonstrated a detectable increase (≥10 %) in FM-LM.
Five of the six subjects that exhibited a detectable increase in either post-therapy gait speed or 6MWD also exhibited
significant (p < 0.01 using a Mann–Whitney U test) increases in electroencephalogram event-related synchronization/
desynchronization. Additionally, two subjects experienced a clinically important increase (≥0.16 m/s) in gait speed, and
four subjects experienced a clinically important increase (≥20 %) in 6MWD. Linear mixed models of gait speed,
dorsiflexion AROM, 6MWD, and FM-LM scores suggest that BCI-FES therapy is associated with an increase in lower
motor performance at a statistically, yet not clinically, significant level.
Conclusion: BCI-FES therapy is safe. If it is shown to improve post-stroke gait function in future studies, it could
provide a new gait rehabilitation option for severely impaired patients. Formal clinical trials are warranted.
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Introduction
Strokes are the leading cause of long-term disability in the
U.S. with over 795,000 new cases each year [1], a number
that will grow as the population ages and stroke survival
rates increase. Despite physiotherapy and spontaneous re-
covery, ∼2 million stroke survivors in the U.S. suffer from
long-term gait deficits. Post-stroke gait disability contributes
to decreased participation in physical, social, and profes-
sional activities [2, 3], thereby exacerbating co-morbidities
such as diabetes, cardiovascular disease, and depression [1].
The inability to dorsiflex the ankle during the swing
phase of the gait cycle, known as foot drop, can contribute
to gait problems, such as reduced walking speed [4, 5].
Many studies have shown that the use of an ankle-foot
orthosis, which specifically corrects foot drop, improves
gait velocity in stroke survivors [6–9]. Currently available
orthoses and assistive gait devices (e.g. walkers and func-
tional electrical stimulation [FES] devices) have not been
shown to provide lasting effects after removal [10, 11].
Therefore, novel therapies that provide substantial, long-
term gait improvement for stroke survivors are urgently
needed.
There has been a growing interest in employing brain-
computer interface (BCI) technology in post-stroke gait
therapy [12–16]. BCIs use computers to translate signals
of the central nervous system (e.g. via electroencephalog-
raphy [EEG]) into control commands for external devices,
providing peri-infarct areas with effector control in cor-
tical strokes or bypassing the lesion in subcortical strokes.
It has been hypothesized that by coupling the activation of
upper motor neurons (UMNs) in the post-stroke cerebral
cortex with the activation of α lower motor neurons (e.g.
via functional electrical stimulation), lasting neurological
and functional improvement may be achieved through a
Hebbian learning process [17]. Utilizing a BCI ensures
that patients are activating UMNs while receiving FES
therapy, as opposed to passive (nonvolitional) electrical
stimulation which may have less therapeutic potential
[18]. Several reports on the implementation of brain-
controlled FES systems [12–14] [19] and their application
to stroke rehabilitation [13, 14, 20] have emphasized its
promise as a new physiotherapeutic modality. However,
no studies have systematically assessed safety and efficacy
with behavioral outcomes, an important step before large-
scale clinical trials can be performed. Although EEG and
FES are quite safe separately, it is unknown whether they
could promote maladaptive motor control and cause a de-
terioration in gait function when they are used in combin-
ation. For example, animal studies had shown that
untimely coactivation of pre- and post-synaptic neurons
can lead to long-term synaptic depression [21].
This Phase I clinical trial examined the safety of a novel
foot-drop-targeted BCI-FES physiotherapy in a cohort of
chronic stroke survivors using a previously developed
system [12, 19]. Additionally, since this BCI-FES therapy
may alleviate foot drop, and subsequently lead to an in-
creased gait velocity [22], post-hoc analyses were per-
formed to explore its potential efficacy and uncover any
associated brain physiological changes.
Methods
Study design
The study was approved by the University of California,
Irvine, Institutional Review Board. Qualified chronic stroke
subjects participated in 12 sessions of BCI-FES therapy for
foot drop. Each subject first underwent the following base-
line assessments: fast gait speed, dorsiflexion active range
of motion (AROM), six-minute walk distance (6MWD),
and Fugl-Meyer leg motor (FM-LM) score. The BCI-FES
therapy was then administered at a rate of three one-hour
sessions per week over the course of four weeks. The
system was designed to detect when the subject was
trying to dorsiflex his/her paretic foot, using EEG, and
deliver electrical stimulation to the appropriate deep
peroneal nerve. Neurological and functional assessments
were performed immediately prior to every third session,
as well as one week and four weeks after the 12th session.
The schedule of activities is summarized in Fig. 1. A
before-and-after comparison was used to determine if
any of the outcome measures deteriorated significantly.
Subject recruitment
Advertisements were used to recruit stroke survivors (>6
mo post-stroke) with gait impairment that included foot
drop. The entry criteria were: (1) age >18, (2) ability to
walk ≥10 m without the use of an ankle-foot orthosis or
assistance by another person (walking aids, e.g. a cane or
walker, were permitted but had to be used consistently),
(3) sufficient cognitive and language function to follow
study-related instructions reliably. The exclusion criteria
were: (1) absence of a tibialis anterior response to FES,
(2) inability to tolerate FES, (3) presence of electronic
implants, (4) severe spasticity or plantarflexion contracture
(Modified Ashworth scale = 4). Although subjects were
allowed to continue their personal exercise programs, initi-
ating new rehabilitative treatments or physiotherapies
during the study would result in exclusion from the study.
BCI-FES dorsiflexion therapy
Qualified subjects underwent 12 one-hour long sessions
of the experimental BCI-FES dorsiflexion therapy, gener-
ally performed at a rate of three sessions per week across
four weeks. Before each session, the subjects were fitted
with an EEG cap (10-10 International Standard), and im-
pedances were reduced to <10 kΩ for a fixed 32-channel
set. To provide the system with training EEG data, sub-
jects followed 100 alternating six-second-long cues to
relax or dorsiflex the paretic foot. Subjects were visually
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monitored for mirror movements (involuntary move-
ments of a limb that are synchronous with the voluntary
movements of the contralateral limb [23]) and co-
contractions at other limbs, and were asked to discon-
tinue these if they occurred. However, compliance with
these instructions was not formally measured. The
training data were recorded at 256 Hz with a NeXus-32
bioamplifier (Mind Media, Herten, Netherlands) to generate
a session-specific decoding model for online operation
(methods in [24–26]). This model could distinguish id-
ling from dorsiflexion using EEG. Finally, surface FES
electrodes were placed over the proximal course of the
deep peroneal nerve (paretic side only), and stimulation
parameters were adjusted to achieve ~15° dorsiflexion
from the neutral position without discomfort.
During each one-hour-long session, subjects performed
as many online BCI-FES runs as possible. Each run con-
sisted of 10 alternating, contiguous 10-s-long dorsiflex/
relax cues, during which the BCI-FES system detected the
subjects’ intention to dorsiflex (or relax) from EEG and
correspondingly provided (or withheld) stimulation. The
accuracy of BCI operation was calculated as the percent-
age of correctly determined BCI-states at a rate of four
decisions per second (decisions were calculated every
0.25 s based on the most recent 0.75 s of EEG data [24]).
Subjects were informed of the possibility of erroneous
recognition of the idle and dorsiflexion states by the BCI.
If FES was erroneously delivered when no movement was
intended, subjects were instructed to ignore the stimula-
tion and continue to relax; when movement was intended
but no FES was delivered, subjects were instructed to
continue to attempt dorsiflexion. Mirror movements and
co-contractions were monitored visually. Brief breaks were
provided between runs, or when requested, to prevent
fatigue of the deep peroneal nerve and tibialis anterior
muscle.
Neurological and functional assessments
Neurological and functional measurements (fast gait speed,
dorsiflexion AROM, 6MWD, and FM-LM score) were
performed before, during, and after the BCI-FES ther-
apy, and are defined below:
 Gait Speed: Fast gait speed [27] was measured
[28] for the middle 6-m section of a 10-m
walkway. This test was repeated 5 times at
each assessment, and the average speed was
calculated [29]. AFOs were removed, but walking
aids such as walkers and canes were allowed.
If a subject did use a walking aid at their first
baseline assessment, they were asked to continue
to use the same device throughout the rest of the
study.
 Dorsiflexion AROM: The subject was placed in a
seated position with the knee flexed at 90° and the
tibial shank perpendicular to the ground. A
goniometer was used to measure the AROM at the
ankle as the subject dorsiflexed, using standard
technique [30].
 6 min Walk Distance: Assessed as the distance that
subjects can ambulate (at a safe, casual speed) in
6 min [31]. AFOs were removed, but walking aids
were permitted.
 Fugl-Meyer Leg Motor Score: Assessed using the
FM measurement system as defined in [32, 33].
Although chronic stroke subjects are assumed to have
reached a plateau in terms of spontaneous behavioral re-
covery [34, 35], three baseline assessments (see Fig. 1)
were performed to account for day-to-day variance [36].
Assessments were also performed immediately prior to
every third BCI-FES session and again one week and four
weeks after the 12th session. Subjects were also asked to
maintain a fall diary throughout the study. The results of
this diary were documented at each weekly functional
assessment.
Outcome measures
All pre-stated outcome measures focused on safety. The
primary outcome was the proportion of subjects who
Fig. 1 Schedule of activities for each subject. Interval Assessments 1, 2, and 3 were performed immediately before BCI-FES therapy sessions 4, 7,
and 10, respectively
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demonstrated a deterioration in gait speed ≥0.16 m/s at
either the one-week or four-weeks post-therapy assess-
ment. This threshold was chosen as it may be associated
with a change in the modified Rankin Scale (mRS) for the
post-stroke population [37]. The secondary outcome mea-
sures included the proportion of subjects who experienced
a significant deterioration in dorsiflexion AROM, 6MWD,
and FM-LM score at either the one-week or four-weeks
post-therapy assessment. Deterioration of dorsiflexion
AROM is defined as a ≥2.5° decrease from average
baseline. There is no established minimum clinically
important change in dorsiflexion AROM, so this
threshold was chosen as it represents the minimal
detectable difference [38]. The minimum clinically
significant change in 6MWD is 20 % [39], while that of
the FM-LM score is hypothesized to be 10 % [40].
Post-Hoc analyses
Additional analyses were performed to determine the
proportion of subjects who demonstrated a detectable
increase in gait speed (≥0.06 m/s [37, 39]), dorsiflexion
AROM (≥2.5°), 6MWD (≥10 % [41]), and FM-LM score
(≥10 %) from average baseline at both post-therapy assess-
ments. Detectable changes are not necessarily clinically
important, so the proportion of subjects that experienced
a clinically significant increase in gait speed (≥0.16 m/s)
and 6MWD (≥20 %) was also calculated. Furthermore, the
effect of BCI-FES therapy on gait speed, dorsiflexion
AROM, 6MWD, and FM-LM was determined using in-
dependent linear mixed models (LMMs) with outcomes
(gait speed, etc.) as a function of therapy group (pre-
therapy baseline or post-therapy) with the random ef-
fects being subjects (and their interaction with therapy
group) and repetitions within subjects (and their inter-
action with therapy group).
The training EEG datasets were analyzed for each
session to determine if subjects experienced any brain
changes throughout the course of the therapy. To re-
veal any spatial changes associated with therapy, the
dorsiflexion-related importance (the μ-measure defined
in [42]) of each EEG channel was plotted for all training
sessions (details in Additional file 1). Additionally,
changes in event-related synchronization (ERS) and
event-related desynchronization (ERD) throughout the
therapy were analyzed as follows. The most important
channel (highest average μ across all sessions) was
identified for each subject, and the EEG data from this
channel were aggregated by week. The median ERS and
ERD at each frequency (8–30 Hz in 2 Hz bins) were
calculated for weeks two through four (Equations 2 and
3 in Additional file 1) and compared to their respective
week-one value using repeated Mann–Whitney U tests
(Bonferroni corrected α = 0.01).
Results
Overview
Nine subjects provided their informed consent to par-
ticipate in the study (Table 1). All subjects completed
the baseline and interval assessments, 12 sessions of
BCI-FES therapy, and the one-week post-therapy assess-
ment. Subject S1 suffered a recurrent stroke after the
one-week post-therapy assessment, and therefore the
four-weeks post-therapy assessment could not be ob-
tained. Subject S2 could not be contacted for the four-
weeks post-therapy assessment. Subject S6 experienced
leg pain during Interval Assessment 2 and declined the
6MWD test. The subjects averaged 8.4 BCI-FES runs per
session. Almost 95 % of the total number of BCI-FES
runs across all subjects and sessions were at a signifi-
cant performance level (α = 0.01) compared to Monte-
Carlo simulation (details in [24]; see Table 1).
Primary outcome measure
No subjects demonstrated a clinically significant decrement
in gait speed at either the one-week (subjects S1-S9) or
the four-weeks (subjects S3-S9) post-therapy assess-
ment (see Fig. 2). The test-retest reliability [43, 44] of
the gait speed measurements, >0.98, was comparable to
reported values [41, 45]. Post-hoc analysis revealed that
five out of nine subjects (56 %) exhibited a detectable in-
crease in gait speed at both post-therapy assessments. S9
experienced a detectable increase in gait speed at one
week post-therapy that disappeared by the last assess-
ment. S6 experienced a detectable increase in gait
speed only at four weeks post-therapy. Additionally, two
of nine subjects (22 %) experienced a clinically important
increase in gait speed (≥0.16 m/s) at both post-therapy as-
sessments. S6 experienced a clinically important increase
in gait speed only at four weeks post-therapy. Note that
although these increases may be clinically relevant, they
are not necessarily statistically significant. With a pre-post
therapy slope of 0.025 (p ≤ 0.03; intercept = 0.63), the
LMM demonstrated that BCI-FES therapy may be associ-
ated with an increase in gait speed.
Secondary outcome measures
No subjects experienced a deterioration in dorsiflexion
AROM, 6MWD, or FM-LM score at either the one-week
or four-weeks post-therapy assessment (Figs. 3, 4 and 5).
Post-hoc analysis revealed that three out of nine subjects
(33 %) had a detectable (≥2.5°) increase in dorsiflexion
AROM at both post-therapy assessments. Five subjects
(out of nine) had detectable increase by the first post-
therapy assessment, while only two subjects (out of seven)
retained this increase at four weeks post-therapy. With a
pre-post therapy slope of 0.84 (p = 0.013; intercept = 4.22),
the LMM demonstrated that BCI-FES therapy may be
associated with an increase in dorsiflexion AROM. The
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Table 1 Demographic and BCI performance data for all subjects

























S1 83/M 29 I L basal ganglia R hemiparesis 5 90 0 23/27 AFO N 107 82.7
S2 59/F 9 I R internal capsule L hemiplegia 8 60 4 21/25 AFO + C N 98 79.1
S3 35/M 24 H R corona radiata L hemiparesis 6 100 0 29/31 AFO Y 119 61.6
S4 75/M 9 I L putamen/corona
radiata
R hemiparesis 7 75 7 18/21 AFO +W N 111 74.5
S5 51/M 8 I L basal ganglia R foot drop 3 100 6 25/26 AFO N 113 84.2
S6 71/M 102 I R basal ganglia L hemiparesis 2 100 1 25/29 AFO N 97 75.5
S7 66/F 23 I L pons R hemiparesis 5 95 4 21/26 AFO + C N 103 86.9
S8 38/F 24 H R basal ganglia L hemiparesis 5 70 1 23/22 AFO + C N 80 84.1
S9 60/M 19 H R thalamus L hemiparesis 5 100 2 26/26 AFO N 82 88.6
M: male, F: female, I: ischemic, H: hemorrhagic, L: left, R: right AFO: ankle-foot orthosis, C: cane, W: walker, Y: yes, N: no

















Fig. 3 Dorsiflexion active range of motion (AROM) results for all subjects at each baseline (B1, B2, and B3), interval (I1, I2, and I3), and post-therapy (one
week and four weeks) assessment. The red dashed line denotes the threshold of clinically detectable deterioration (2.5° decrease from average
baseline)
Fig. 2 Gait speed measurements for each subject. The results from the baseline (B1, B2, and B3), interval (I1, I2, and I3), and post-therapy (one week
and four weeks) gait speed assessments are shown for all subjects. The error bars shown here represent the within-assessment standard deviation (gait
speed measurements were repeated five times per assessment), while the blue circles represent the within-assessment means. Note that the error bars
are only displayed here to provide insight into the within-assessment standard deviation, and only the means for each assessment [29] were used in
the outcome measures and post-hoc analyses. The red dashed line denotes the threshold of clinically important deterioration (0.16 m/s
decrease from average baseline)
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6MWD increased by ≥10 % from average baseline for
five subjects (56 %) and ≥20 % for four subjects (44 %)
at the post-therapy assessments. S9 experienced a detect-
able increase in 6MWD at both post-therapy assessments,
but only the increase at one week post-therapy was also
clinically important. With a pre-post therapy slope of 8.52
(p = 0.02; intercept = 204.10), the LMM demonstrated that
BCI-FES therapy may be associated with an increase in
6MWD. FM-LM score increased by ≥10 % for subjects S1,
S2, and S7 (33 % of subjects) at the post-therapy assess-
ments. S6 only experienced an increase in FM-LM at the
four-weeks post-therapy assessment. Once again, changes
Fig. 5 Subjects’ Fugl-Meyer leg motor (FM-LM) scores at each baseline (B1, B2, and B3), interval (I1, I2, and I3), and post-therapy (one week and four
weeks) assessment. The red dashed line denotes the threshold of clinically detectable/important deterioration (10 % decrease from average baseline)
Fig. 4 Subjects’ six minute walking distance (6MWD) at each baseline (B1, B2, and B3), interval (I1, I2, and I3), and post-therapy (one week and four
weeks) assessment. The red dashed line denotes the threshold of clinically important deterioration (20 % decrease from average baseline)
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in dorsiflexion AROM, 6MWD, and FM-LM scores per
subject may be clinically significant, but they are not ne-
cessarily statistically significant. With a pre-post therapy
slope of 0.36 (p < 0.001; intercept = 23.81), the LMM dem-
onstrated that BCI-FES therapy may be associated with an
increase in FM-LM score.
Adverse events
Subject S1 reported a recurrent stroke after his one-week
post-therapy assessment. The cause of stroke was idiopathic,
but was suspected to be associated with a prosthetic heart
valve, and was thereby deemed unrelated to the BCI-FES
therapy. Subject S7 reported a fall (not resulting in serious
injury) while carrying a heavy object after the one-week
post-therapy assessment. This was also considered unrelated
to the study procedures. No other adverse events, such
as peroneal nerve dysesthesias or skin breakdown, were
reported.
EEG changes during therapy
Five out of the six subjects that exhibited a detectable
improvement in post-therapy gait (increase in gait speed
or 6MWD) also exhibited a significant increase in ERS and
ERD (83.3 % sensitivity). The remaining three subjects
demonstrated no significant increase in ERS or ERD
(100 % specificity). The evolution of ERS and ERD are
shown in Fig. 6.
For subjects S1, S2, S4, S5, S6, S7, and S8, the most sali-
ent EEG channel for distinguishing idling from dorsiflexion
(highest μ value) was Cz; for S3 and S9, it was C5 and
CPz, respectively. Representative maps of the EEG chan-
nels’ importance for dorsiflexion are shown in Fig. 7
(additional plots in Additional file 1). No subject dem-
onstrated a consistent change in the location of his/her
most salient EEG channel throughout the BCI-FES
therapy.
Subjective reports
Subject S2 indicated at the one-week post-therapy as-
sessment that she could climb stairs for the first time
since her stroke. Subject S4 indicated that his newfound
gait improvement allowed him to walk farther during his
daily exercises. Subject S5 stated that he had better con-
trol of the gas pedal while driving after beginning the
BCI-FES therapy. Although subject S6 felt that the ther-
apy was somewhat tedious, he was enthusiastic about his
improvement in dorsiflexion AROM. Subject S7 felt that
she had more consistent control of foot dorsiflexion and
knee flexion/extension. Subject S9 reported an increased
sensation and strength in his paretic side, leading to what
he considered to be a more natural gait. All reports were
provided or solicited informally at the end of the study.
Discussion
No clinically important deterioration in gait speed, dorsi-
flexion AROM, 6MWT distance, or FM-LM score was
present one week or four weeks after completing the
BCI-FES therapy. Throughout the study, only one fall
was reported, an incidence well below that of conventional
outpatient stroke rehabilitation [46–48]. The lack of de-
terioration in the measured gait characteristics indicates
that the BCI-FES dorsiflexion therapy may be safe to ex-
plore in larger populations of stroke survivors. In addition,
post-hoc analysis revealed that five subjects were walking
detectably faster (≥0.06 m/s) at the post-therapy assess-
ments. Two of these subjects were walking ≥0.16 m/s
faster than average baseline, quite a remarkable feat since
this magnitude is associated with a ≥1 increase in mRS
[37]. Furthermore, the data suggest that BCI-FES therapy
is associated with a statistically significant, albeit not
clinically significant, increase in gait speed, dorsiflexion
AROM, 6MWD, and FM-LM score. Since this study fo-
cused on safety outcomes and was not designed to test
efficacy, any improvement in gait function cannot yet
be attributed to the BCI-FES therapy. Nonetheless, given
that increased gait speed is strongly associated with in-
creased social re-integration after stroke [2], and based
on this therapy’s acceptable early safety profile, larger
clinical trials are warranted to definitively establish its
safety and efficacy.
Given that the BCI-NMES system was inspired by the
concept of Hebbian learning between M1 and foot dorsi-
flexion motor pools [17], increased dorsiflexion AROM
and associated brain changes were expected. However,
increased dorsiflexion AROM generally did not persist
at four weeks post-therapy (verified via an insignificant
LMM slope using post-therapy data from only this as-
sessment), and ERS and ERD changes occurred, instead,
in association with increased gait speed alone. These
increases in ERS and ERD indicate that activation of
foot and leg sensorimotor areas is more synchronous
(Fig. 7 and Additional file 1), and suggest the presence
of an underlying neural process. Possible mechanisms
include Hebbian learning between UMNs and the
spinal cord gait central pattern generators [49] and
increased afferent sensory feedback during electrical
stimulation and walking [50]. It also remains a possi-
bility that modest increases in dorsiflexion strength
(via the Hebbian learning mechanism expected by the
authors) may have occurred, but subsequent increases
in dorsiflexion AROM were obscured by mild plantar
flexion contractures. Ultimately, formal physiological
studies are needed to further elucidate the underlying
mechanism.
Of note, the authors believe that subject S6 experi-
enced problems with walking during the one-week
post-therapy assessment due to a new pair of poorly
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fitting shoes. This is supported by the presence of a
transient drop in his gait speed and 6MWD. By four
weeks post-therapy, these measures surpassed their
baseline values.
Lastly, at the start of the study the mean baseline gait
speed and 6MWD were 0.63 ± 0.40 m/s and 204.1 ±
122.5 m, respectively, lower than that of the chronic
stroke population reported in [51]. One potential strength
of BCI-based movement therapies is that they are access-
ible to individuals with baseline motor functions too low
for other interventions (e.g. treadmill training).
Limitations
The major limitation of this study is the small sample
size and the lack of matched controls and unbiased raters.
Additionally, large, controlled studies, i.e. Phase III clinical
trials, are necessary to definitively establish efficacy. How-
ever, the small sample size is appropriate for an initial
investigation into the safety of this BCI-FES therapy.
Furthermore, all subjects were assumed to have reached
a steady rehabilitative state (>6 months post-stroke) [34],
and were thus used as their own controls. Also, baseline
assessments for all subjects appeared steady. Since the
Fig. 6 Top and Middle: Event-related synchronization (ERS) and desynchronization (ERD) during each week for all subjects. ERS, top, and ERD,
middle, during weeks one through four (wk 1–4, or sessions 1–3, 4–6, 7–9, 10–12, respectively). Boxes signify intervals of one median absolute
deviation around the median (central black bar). Significant positive and negative changes from week one are denoted by a cross-in-circle
symbol and a line-in-circle symbol, respectively. Bottom: Temporal profile of median ERS during weeks one through four, taken from S7. The
cue being presented is denoted by the background (“Dorsiflex”, hatched green; “Relax”, solid red)
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majority of subjects had subcortical strokes, particularly
in the basal ganglia, it will be important to examine how
BCI-FES therapy affects those with cortical strokes in fu-
ture studies. Ankle dorsiflexion was chosen as the target
of FES therapy since studies have concluded that foot drop
plays a role in post-stroke gait impairment [4, 5]. On the
other hand, studies such as [52] stress the important role
of other muscle groups in post-stroke gait impairment.
However, the BCI-FES therapy implemented in this study
can easily be applied to other muscle groups. Finally,
Fig. 7 Importance of each EEG channel for dorsiflexion. Channels are colored based on their μ value, from dark blue (unimportant) to dark red
(highly important). These two representative maps are taken from subject S8 (top) and S9 (bottom)
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although multiple meta-analyses [10, 11] suggest that
functional electrical stimulation alone does not provide
a conclusive long-term therapeutic effect, a formal direct
comparison with BCI-FES therapy may be necessary in
the future.
Conclusions
Since this BCI-FES therapy appears to be safe and a large
proportion of subjects experienced improvements in gait
speed and dorsiflexion AROM, larger controlled studies
(including pre-clinical and Phase II/III studies) are war-
ranted to investigate additional aspects of this novel ther-
apy. These include: (1) the potential efficacy and optimal
duration of BCI-FES therapy, (2) the neurobiological
principles that underlie any functional changes, (3) the
subpopulation of stroke patients that will benefit most,
and (4) any synergism with conventional physiotherapies.
Additional file
Additional file 1: Supplementary material and figures.
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